cbdMD, Inc. announced on April 7, 2025, that its Novel Food dossier (RP793) has advanced to the last phase of regulatory assessment with the UK Food Standards Agency (FSA), nearing final approval. This milestone underscores the company's commitment to safety, quality, and scientific excellence.
The FSA published its safety assessment for cbdMD's proprietary and patent-pending CBD isolate (RP793) on February 28, 2025. This high-purity CBD ingredient, intended for food supplements, was confirmed to meet UK food safety standards and has now progressed to the final Risk Assessment stage.
Ronan Kennedy, CEO of cbdMD, noted that the UK CBD industry is estimated to be a £800 million market this year. Achieving this regulatory clarity is expected to benefit leaders in obtaining FSA approval, driving increased consumer confidence and potentially expanding market share for cbdMD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.